KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Merck (MRK) EBT (2016 - 2026)

Merck has reported EBT over the past 18 years, most recently at -$3.5 billion for Q1 2026.

  • Quarterly EBT fell 159.29% to -$3.5 billion in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $11.7 billion through Mar 2026, down 42.17% year-over-year, with the annual reading at $21.1 billion for FY2025, 5.67% up from the prior year.
  • EBT was -$3.5 billion for Q1 2026 at Merck, down from $3.4 billion in the prior quarter.
  • Over five years, EBT peaked at $6.7 billion in Q3 2025 and troughed at -$5.3 billion in Q2 2023.
  • The 5-year median for EBT is $4.2 billion (2024), against an average of $3.3 billion.
  • Year-over-year, EBT tumbled 218.12% in 2023 and then skyrocketed 303.81% in 2024.
  • A 5-year view of EBT shows it stood at $3.5 billion in 2022, then plummeted by 158.24% to -$2.0 billion in 2023, then skyrocketed by 303.81% to $4.2 billion in 2024, then fell by 17.99% to $3.4 billion in 2025, then plummeted by 202.34% to -$3.5 billion in 2026.
  • Per Business Quant, the three most recent readings for MRK's EBT are -$3.5 billion (Q1 2026), $3.4 billion (Q4 2025), and $6.7 billion (Q3 2025).